{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T12:24:21Z","timestamp":1790857461428,"version":"4.1.0"},"reference-count":33,"publisher":"Baishideng Publishing Group Inc.","issue":"24","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["WJCC"],"published-print":{"date-parts":[[2022,8,26]]},"DOI":"10.12998\/wjcc.v10.i24.8703","type":"journal-article","created":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T13:17:57Z","timestamp":1660310277000},"page":"8703-8708","source":"Crossref","is-referenced-by-count":6,"title":["Recurrent herpes zoster in a rheumatoid arthritis patient treated with tofacitinib: A case report and review of the literature"],"prefix":"10.12998","volume":"10","author":[{"given":"Qing-Xia","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Juan","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Yan","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2060","reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/cells9040880"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2019.102400"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-020-00921-8"},{"key":"B4","unstructured":"Food and Drug Administration. Xeljanz full prescribing information [Accessed 18 March 2019]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfdadocs\/Label\/2018\/203214s018 Lbl.pdf"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key225"},{"key":"B6","unstructured":"Drugs.com.Pfizer announces U.S. FDA approves Xeljanz (tofacitinib) for the treatment of moderately to severely active ulcerative colitis. Drugs.com https:\/\/www.drugs.com\/newdrugs\/pfizer-announces-u-s-fdaapproves-xeljanz-tofacitinib-moderately-severelyactive-ulcerative-colitis-4756.html (2018)"},{"key":"B7","doi-asserted-by":"crossref","unstructured":"Traynor K. FDA approves tofacitinib for rheumatoid arthritis. Am J Health Syst Pharm 2012; 69: 2120","DOI":"10.2146\/news120088"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0701-9"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0835-9"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106210"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key339"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2017.1335574"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1086\/342963"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-016-0430-0"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-4362.2002.15474.x"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofx007"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.05.037"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/art.23112"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-014032"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2018-0113"},{"key":"B21","unstructured":"Hodge JA, Kawabata TT, Krishnaswami S, Clark JD, Telliez JB, Dowty ME, Menon S, Lamba M, Zwillich S. The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Clin Exp Rheumatol 2016; 34: 318-328"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key287"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-1866-2"},{"key":"B24","doi-asserted-by":"crossref","unstructured":"Munasinghe BM, Fernando U, Mathurageethan M, Sritharan D. Reactivation of varicella-zoster virus following mRNA COVID-19 vaccination in a patient with moderately differentiated adenocarcinoma of rectum: A case report. SAGE Open Med Case Rep 2022; 10: 2050313X221077737","DOI":"10.1177\/2050313X221077737"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/art.38745"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23769"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/art.40189"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izy150"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209131"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210457"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/art.41655"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.03.017"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/art.40187"}],"container-title":["World Journal of Clinical Cases"],"original-title":[],"link":[{"URL":"https:\/\/www.wjgnet.com\/2307-8960\/full\/v10\/i24\/8703.htm","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T13:20:11Z","timestamp":1660310411000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.wjgnet.com\/2307-8960\/full\/v10\/i24\/8703.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,26]]},"references-count":33,"journal-issue":{"issue":"24"},"URL":"https:\/\/doi.org\/10.12998\/wjcc.v10.i24.8703","relation":{},"ISSN":["2307-8960"],"issn-type":[{"value":"2307-8960","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8,26]]}}}